Posts Tagged pharma
The delivery of Theresa May’s letter to European Council president Donald Tusk triggering Article 50, and the official start of the UK’s two-year process of negotiating its divorce from the EU, made the choice of this month’s PME cover an easy one.
Inside the issue there’s a great look at the implications of Brexit for pharma, with Nicola Maguire from law firm Cooley LLP rounding up the industry’s areas of concern, Alexa Forbes from Four health Communications asks ‘can UK pharma rise to the post-Brexit challenge’ and greyhealth group’s Paul Hughes looks at the facts (and the alternative facts) of the situation.
Meanwhile, in a series of exclusive interviews with PME, Japanese pharmaceutical companies pull no punches when it comes to what the reassurance they want from the UK on its future in science and innovation. Read the rest of this entry »
You won’t generally find PME issues following a particular theme each month – there’s simply too much interesting ground to cover in the magazine for that.
Nevertheless, as each issue coalesces there are often common strands across different features and such seemed the case with March’s PME, which contains a nice chunk of ‘careers’ content. Read the rest of this entry »
As PME‘s first issue of the year comes out the European pharmaceutical industry goes into 2017 steeling itself for the start of Brexit, with plenty of words already devoted to what we don’t know about the implications of the UK’s vote to leave the European Union.
This year should see the phony war end and hostilities begin in earnest when the UK formally triggers Article 50 and commences the official process of withdrawing from the EU. Read the rest of this entry »
For this month’s issue of PME I spoke with Ipsen’s new chief executive David Meek about his company’s strategy for growth and – appropriately enough, as we sat down at the ESMO meeting in Copenhagen – his hopes for Ipsen’s new cancer drug Cabometyx.
We covered the strategic pillars Ipsen is counting on for success and looked at the strong progress the French firm is making in the US – where for the first year its operations there are its number one affiliate by revenue – and the changes to its primary care business model in China. Read the rest of this entry »
There’s no shortage of ambition at GlaxoSmithKline, whose chief immunology officer and senior vice president of their R&D pipeline Paul-Peter Tak we spoke to for this month’s executive interview.
Having joined the company five years ago from an academic medical centre in Amsterdam, he says he was driven to move to the industry because he wanted to have a bigger impact on patients’ lives. Read the rest of this entry »
July was always going to be busy, but August too seems to have flown by thanks to holidays, holiday cover and some interesting projects that have come my way.
So, there’s just time for a quick July-August post on the last couple of months, which began in traditional style with the 19th Communiqué Awards in London on July 7. You can see the full results here and register interest for next year’s awards here. Read the rest of this entry »
This month PME looks how companies are being forced to diversify and specialise their business models, we round up the industry implications of Brexit speak to Sobi’s UK and Ireland general manager Neil Dugdale about the opportunities to tackle rare diseases in the UK.